Drug Search Results
More Filters [+]

Lobeglitazone

Alternative Names: lobeglitazone, duvie, ckd-501, ckd501, ckd 501
Latest Update: 2024-07-09
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PPAR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Korea

Approved Indications: None

Known Adverse Events: None

Company: Chong Kun Dang
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lobeglitazone

Countries in Clinic: Korea

Active Clinical Trial Count: 3

Highest Development Phases

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A101_05BE2315

P1

Completed

Type 2 Diabetes

2024-04-29

A101_03BE2112

P1

Completed

Type 2 Diabetes

2023-07-23

50%

A101_03BE2112

P1

Completed

Type 2 Diabetes

2023-07-23

50%

A101_03BE2112

P1

Completed

Type 2 Diabetes

2023-07-23

50%

A101_03BE2112

P1

Completed

Type 2 Diabetes

2023-07-23

50%

A101_04BE2113

P1

Completed

Type 2 Diabetes

2023-06-04

50%

A101_04BE2113

P1

Completed

Type 2 Diabetes

2023-06-04

50%

A101_04BE2113

P1

Completed

Type 2 Diabetes

2023-06-04

50%

Recent News Events